These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30353601)

  • 21. Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
    Tikhonova IA; Jones-Hughes T; Dunham J; Warren FC; Robinson S; Stephens P; Hoyle M
    Pharmacoeconomics; 2018 Jan; 36(1):39-49. PubMed ID: 28914440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.
    Hammer KJ; Copeland VC; Loggers ET; Pollack SM; Wagner MJ; Cranmer LD
    Am J Clin Oncol; 2020 Jun; 43(6):446-451. PubMed ID: 32235164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
    Chugh R; Griffith KA; Davis EJ; Thomas DG; Zavala JD; Metko G; Brockstein B; Undevia SD; Stadler WM; Schuetze SM
    Ann Oncol; 2015 Jul; 26(7):1459-64. PubMed ID: 25858498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
    Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
    Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.
    Cote GM; Haddox CL; Choy E; Merriam PA; Mazzola E; Venkataraman V; Alcindor T; Wagner AJ; Demetri GD; George S
    Clin Cancer Res; 2024 Jul; 30(13):2702-2708. PubMed ID: 38723278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma.
    Schöffski P; Bahleda R; Wagner AJ; Burgess MA; Junker N; Chisamore M; Peterson P; Szpurka AM; Ceccarelli M; Tap WD
    Clin Cancer Res; 2023 Sep; 29(17):3320-3328. PubMed ID: 37382656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.
    Schliemann C; Hemmerle T; Berdel AF; Angenendt L; Kerkhoff A; Hering JP; Heindel W; Hartmann W; Wardelmann E; Chawla SP; de Braud F; Lenz G; Neri D; Kessler T; Berdel WE
    Eur J Cancer; 2021 Jun; 150():143-154. PubMed ID: 33901793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy.
    Davis EJ; Chugh R
    Drug Des Devel Ther; 2017; 11():3579-3587. PubMed ID: 29263653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
    Blay JY; von Mehren M; Samuels BL; Fanucchi MP; Ray-Coquard I; Buckley B; Gilles L; Lebedinsky C; Elsayed YA; Le Cesne A
    Clin Cancer Res; 2008 Oct; 14(20):6656-62. PubMed ID: 18927308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olaratumab in soft tissue sarcoma - Current status and future perspectives.
    Antoniou G; Lee ATJ; Huang PH; Jones RL
    Eur J Cancer; 2018 Mar; 92():33-39. PubMed ID: 29413687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.
    Chawla SP; Chua VS; Hendifar AF; Quon DV; Soman N; Sankhala KK; Wieland DS; Levitt DJ
    Cancer; 2015 Feb; 121(4):570-9. PubMed ID: 25312684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS).
    Lewin J; Malone E; Al-Ezzi E; Fasih S; Pedersen P; Accardi S; Gupta A; Abdul Razak A
    Eur J Cancer; 2021 Feb; 144():360-367. PubMed ID: 33418486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma.
    Van Tine BA; Hirbe AC; Oppelt P; Frith AE; Rathore R; Mitchell JD; Wan F; Berry S; Landeau M; Heberton GA; Gorcsan J; Huntjens PR; Soyama Y; Vader JM; Alvarez-Cardona JA; Zhang KW; Lenihan DJ; Krone RJ
    Clin Cancer Res; 2021 Jul; 27(14):3854-3860. PubMed ID: 33766818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olaratumab for the treatment of soft tissue sarcoma.
    Deshpande HA; Cecchini M; Ni Choileain S; Jones R
    Drugs Today (Barc); 2017 Apr; 53(4):247-255. PubMed ID: 28492292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
    Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
    Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
    Ganjoo KN; Cranmer LD; Butrynski JE; Rushing D; Adkins D; Okuno SH; Lorente G; Kroll S; Langmuir VK; Chawla SP
    Oncology; 2011; 80(1-2):50-6. PubMed ID: 21625179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.
    Wagner AJ; Kindler H; Gelderblom H; Schöffski P; Bauer S; Hohenberger P; Kopp HG; Lopez-Martin JA; Peeters M; Reichardt P; Qin A; Nippgen J; Ilaria RL; Rutkowski P
    Ann Oncol; 2017 Mar; 28(3):541-546. PubMed ID: 28426120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olaratumab for soft tissue sarcoma.
    Teyssonneau D; Italiano A
    Expert Opin Biol Ther; 2017 Aug; 17(8):1019-1025. PubMed ID: 28691538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
    Gerber DE; Swanson P; Lopez-Chavez A; Wong L; Dowlati A; Pennell NA; Cronier DM; Qin A; Ilaria R; Cosaert J; Shahir A; Baggstrom MQ
    Lung Cancer; 2017 Sep; 111():108-115. PubMed ID: 28838379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.